How should ketorolac be administered intravenously, including appropriate dose, dilution, infusion rate, and contraindications?

How to Give Ketorolac Intravenously

Administer ketorolac IV as a slow bolus over at least 15 seconds at doses of 15-30 mg for adults under 65 years, or 15 mg for adults 65 years and older, with dosing every 6 hours not exceeding 5 days of total therapy. 1

Dosing Guidelines

Adult Dosing (FDA-Approved)

Single-Dose IV Administration:

• Patients <65 years: 30 mg IV 1
• Patients ≥65 years, renally impaired, or <50 kg: 15 mg IV 1

Multiple-Dose IV Administration:

• Patients <65 years: 30 mg IV every 6 hours (maximum 120 mg/day) 1
• Patients ≥65 years, renally impaired, or <50 kg: 15 mg IV every 6 hours (maximum 60 mg/day) 1

Pediatric Dosing

For children undergoing surgery, the recommended approach is:

• Intraoperative single dose: 0.5-1 mg/kg up to 30 mg maximum 2
• Postoperative short-term therapy: 0.15-0.2 mg/kg (maximum 10 mg) every 6 hours for maximum 48 hours 2

Important pediatric consideration: Lower doses (0.5 mg/kg) are safer than higher doses (0.9-1 mg/kg) for tonsillectomy, as higher doses significantly increase primary operative bleeding risk (OR 4.07) while 0.5 mg/kg provides adequate pain control without increased bleeding 3

Cesarean Delivery Context

For cesarean delivery, administer 15-30 mg IV at the end of surgery in the absence of contraindications as part of multimodal analgesia 4

Administration Technique

Critical administration requirement: The IV bolus must be given over no less than 15 seconds 1. This slow administration is essential to avoid pronounced hemodynamic effects observed with rapid boluses.

Preparation and Compatibility

• Available concentrations: 15 mg/mL or 30 mg/mL 1
• Do NOT mix in a syringe with: morphine sulfate, meperidine, promethazine, or hydroxyzine—this causes precipitation 1
• Inspect visually for particulate matter and discoloration before administration 1
• Store at 20-25°C and protect from light 1

Duration of Therapy

Maximum duration: 5 days 1. The FDA explicitly limits ketorolac to short-term use (≤5 days) for moderately severe acute pain requiring opioid-level analgesia, typically in postoperative settings.

Exception for palliative care: Prolonged continuous IV infusions have been reported in cancer patients with intractable bone pain when benefits outweigh risks, but this requires intensive monitoring and is off-label 5, 6

Dose-Response Evidence

An analgesic ceiling effect exists at 10 mg IV 7. A high-quality 2017 randomized controlled trial demonstrated that 10 mg, 15 mg, and 30 mg IV ketorolac all provided similar pain reduction at 30 minutes (mean NRS reduction ~2.5-3 points) with no statistical differences between groups 7. This suggests that doses above 10 mg offer no additional analgesic benefit while potentially increasing adverse event risk.

A 2023 systematic review confirmed that low-dose ketorolac (10-20 mg) is probably as effective as high-dose (≥30 mg) for pain relief, though low-dose may increase need for rescue analgesia 8

Contraindications and Precautions

Correct hypovolemia before administration 1

Key contraindications:

• Peptic ulcer disease or gastrointestinal hemorrhage
• Renal or hepatic insufficiency
• NSAID allergies
• Pregnancy or breastfeeding
• Severe hemodynamic instability (SBP <90 or >180 mmHg, HR <50 or >150 bpm) 7

Monitoring requirements:

• Renal function (especially in elderly, volume-depleted, or renally impaired patients)
• Bleeding parameters (ketorolac reversibly inhibits platelet function)
• For prolonged use beyond 5 days (off-label): intensive clinical and laboratory monitoring 5

Clinical Pearls

• Opioid-sparing effect: Ketorolac combined with opioids provides synergistic analgesia, allowing 35-44% reduction in morphine consumption 9
• For breakthrough pain: Do not increase ketorolac dose or frequency; instead supplement with low-dose opioids 1
• Switch to oral analgesics as soon as possible to minimize exposure duration 1
• Elderly patients require dose reduction due to increased risk of adverse events, not pharmacokinetic differences 1

The evidence strongly supports using the lowest effective dose (10-15 mg IV) for most adult patients, reserving 30 mg doses only for younger patients without risk factors, and strictly adhering to the 5-day maximum duration unless exceptional circumstances warrant prolonged use with intensive monitoring.